# Biocytogen Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biocytogen-biotechnology

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.biocytogen.com
- Total disclosed funding: $291M
- Latest round: Series E (Jun 22, 2021)
- Investors on record: 12

## About

Founded in 2008 and based in Beijing, China, Biocytogen Biotechnology is a biotechnology company that engages in the research and development innovative antibody drugs for oncology, autoimmune, metabolic and anti-infection-related diseases. The company's founder and CEO, Shen Yuelei, received a PhD in Immunology from the University of Massachusetts School of Medicine. He has nearly 30 years of experience in immunology, gene editing, model animal disease model development, and antibody drug development.

The drugs developed by the company include monoclonal antibodies, bispecific antibodies, ADC drugs, etc. In addition, relying on the self-developed fully human antibodies RenMab, RenLite and other mouse platforms, through the integration of mouse target gene knockout technology, high-throughput single B cell antibody discovery technology, and rapid animal efficacy evaluation in vivo platform, the company has developed a large-scale research and development plan for innovative target antibodies. Through this plan, the company will conduct antibody discovery and in vivo drug efficacy screening on potential antibody drug targets, focusing on the discovery of drug targets and lead antibody molecules with first-in-class and best-in-class potential.

The company generates revenue from developing innovative antibody drugs for oncology, autoimmune, metabolic and anti-infection-related diseases.

In December 2025, Biocytogen Biotechnology raised CNY 1.267 billion in an IPO, selling 47.5 million shares at CNY 26.68 per share on the STAR Market.

## Funding rounds

- Series E, Jun 22, 2021 — OrbiMed Advisors, CPE Funds Management, Lake Bleu Capital, Octagon Capital Investments
- Series D, Sep 15, 2020, $143M — Cowin Capital, PICC Capital Equity Investment, CMB International Asset Management, 3E Bioventures Capital, SDIC Venture Capital, China Life Capital
- Series D, Aug 8, 2019, $77M — CMB International Asset Management, 3E Bioventures Capital, SDIC Venture Capital, China Life Capital
- Series C, Apr 10, 2018, $65M — Oriza Holdings, Cowin Capital, CMB International Asset Management, 3E Bioventures Capital, SDIC Venture Capital
- Series B, Oct 1, 2015 — BVCF Capital, SDIC Venture Capital
- Series A, Aug 19, 2013, $5.7M — BVCF Capital

## Investors

- BVCF Capital — Series A, Series B
- SDIC Venture Capital (https://capitalatlas.ai/funds/sdic-venture-capital) — Series B, Series C, Series D
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series C
- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Series C, Series D
- CMB International Asset Management (https://capitalatlas.ai/funds/cmb-international-asset-management) — Series C, Series D
- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series C, Series D
- China Life Capital — Series D
- PICC Capital Equity Investment (https://capitalatlas.ai/funds/picc-capital-equity-investment) — Series D
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series E
- CPE Funds Management (https://capitalatlas.ai/funds/cpe-funds-management) — Series E
- Lake Bleu Capital (https://capitalatlas.ai/funds/lake-bleu-capital) — Series E
- Octagon Capital Investments (https://capitalatlas.ai/funds/octagon-capital-investments) — Series E